Impacting society, creating change
Technologies developed at Ohio State are changing the world. Learn more about the startups that are a part of the Ohio State portfolio.
Search for a Startup below
TRIM-edicine is developing novel protein therapeutics and biologics to treat unmet medical needs, such as acute and chronic tissue injuries, muscular dystrophy, cancer, aging and diabetes. Novel therapeutic approaches involve the MG53, MG29, and ATAP proteins.
Sirona Therapeutics is commercializing an oral patch that delivers chemopreventive drugs directly to pre-cancerous oral lesions, reducing toxicity and adverse side effects.
Prelude Therapeutics is focused on the discovery and development of differentiated small-molecule drugs targeting gene regulation for cancer and rare diseases.
OncoImmune specializes in therapeutics for cancer, inflammation and autoimmune diseases. OncoImmune’s lead compound CD24Fc is a clinical stage asset targeting the CD24-Siglec axis that regulates host inflammatory response to tissue injuries. This has broad implications in the pathogenesis of autoimmune diseases, cancer and graft-versus-host disease. OncoImmune has received orphan drug designation for CD24Fc in both the United States and Europe.
NeurXStem produces synthetic neural organoids from iPSC-derived skin cells that closely replicate the human central nervous system in a dish. This Neural Organoid Platform™ meets high scientific metrics of reliability, reproducibility and robustness. This makes the platform highly suitable for pre-clinical research and development to identify and evaluate potential drugs for toxicity, safety and efficacy on model systems that accurately mimic human functions.